Drug Discovery

LIGAND-AI, a €60M international initiative led by Pfizer and SGC with UCL, will publish large protein-ligand datasets and AI models to speed drug discovery for rare, neurological and cancer targets.

An AI-designed molecule has moved into Phase 1 trials after a high-profile partnership and funding round. What this milestone means for drug timelines, investors, and patients.

Explore how AI shortens drug discovery timelines, improves target selection and compound design, and what this means for new treatments and patient care.

How AI is accelerating RNA drug discovery with data-driven models, deep learning, and interactive workflows, cutting costs and timelines for pharma and investors.

PreciseDx joins industry leaders at the NYC Leadership Summit to discuss AI-driven drug discovery, PreciseBreast, and the balance between innovation and regulation.

Medra closed a $52M Series A to expand robotic labs and ‘Physical AI Scientists’ that link AI predictions to real experiments, speeding drug discovery for patients.

AI is shortening drug discovery timelines by improving target identification, compound optimization and trial matching. What this means for patients and pharma.

Discover how AI and explainable models like Ignota Labs’ SAFEPATH identify toxicity mechanisms to repurpose shelved drugs, cutting costs and carbon footprints.

Explore how AI platforms such as MMV’s MAIP and dd4gh speed malaria drug discovery and make advanced tools accessible to scientists in low- and middle-income countries.

Explore how generative AI and automation are transforming drug discovery with faster design, synthesis, and testing cycles. Learn about business impact and future prospects.